TOTAL: $446M | |||||
Company |
Type Of |
Number Of |
Amount |
Investors; Placement Agents; Details |
Date |
Advaxis Inc. (Princeton, N.J.) |
Private placement |
N/A |
$10 |
Advaxis secured $10M in equity financing from Magna Group LLC |
11/1/12 |
Amarantus BioSciences Inc. (Sunnyvale, Calif.) |
Private placement |
N/A |
$1.1 |
Amarantus secured $1.1M in funding through two separate transactions, by issuing a convertible promissory note to an undisclosed investor in the principal amount of $600,000 and, with an institutional fund, settled more than $500,000 in accounts payable |
11/15/12 |
Ambit Biosciences Inc. (San Diego) |
Private placement |
N/A |
$50 |
Ambit raised $50M from existing investors, including OrbiMed Advisors, Aisling Capital, Apposite Healthcare, Roche Ventures, GrowthWorks, MedImmune Ventures, Forward Ventures, GIMV and Radius Ventures |
11/7/12 |
Arno Therapeutics Inc. (Flemington, N.J.) |
Private placement of convertible debentures |
W for 42.35S and W for 42.85S |
$12.7 |
The debentures are convertible to common stock at 30 cents per share; Arno also is issuing five-year warrants for 42.35 million shares at 50 cents apiece and 18-month warrants for 42.85 shares at 30 cents per share |
11/28/12 |
Athersys Inc. (Cleveland) |
Private placement |
22.8S |
$23 |
Athersys placed 22.8M shares with new and existing investors to raise $23M |
11/7/12 |
BioDelivery Sciences International Inc. (Raleigh, N.C.) |
At-market registered direct financing |
6.8S and 2.7S of Series A |
$40 |
BioDelivery received commitments from institutional investors for an at-market registered direct financing for gross proceeds of $40M; BDSI will sell 6.8M shares of common stock and 2.7M shares of newly designated Series A convertible preferred stock, both at $4.21 apiece; William Blair & Co. LLC acted as sole lead placement agent for the offering, with JMP Securities LLC and Roth Capital Partners LLC acting as co-placement agents |
11/29/12 |
Compugen Ltd. (Tel Aviv, Israel) |
Equity financing |
N/A |
$15 |
An unnamed private U.S.-based investment company is providing $15M in milestone-related equity funds; the new investor will obtain a majority equity interest in Compugen's subsidiary, Keddem Bioscience Ltd., with Compugen maintaining a minority interest |
11/20/12 |
Curis Inc. (Lexington, Mass.) |
Loan |
N/A |
$30 |
Curis gained access to $30M by pulling down a loan against Erivedge royalties |
11/29/12 |
Idera Pharmaceuticals Inc. (Cambridge, Mass.) |
Private placement of shares |
0.424S and W for 8.485S |
$7 |
Idera raised $7 million by issuing 424,242 shares of its convertible preferred stock (convertible into 8.485M shares of common stock) and warrants to purchase 8,485M shares of common stock; the securities were sold to Pillar Pharmaceuticals II LLP |
11/13/12 |
Intarcia Therapeutics Inc. (Hayward, Calif.) |
Private placement |
N/A |
$210 |
Intarcia completed two financings with total proceeds of $210M consisting of $160M from a preferred stock private placement and $50M from a private debt placement; investors were New Enterprise Associates Inc., New Leaf Venture Partners and Venrock, along with The Baupost Group LLC, Farallon Capital Management LLC; Morgan Stanley acted as sole placement agent for the debt and lead placement agent for the equity, with Leerink Swann LLC acting as co-placement agent on the equity |
11/16/12 |
Isconova AB (Uppsala, Sweden) |
Rights issue |
N/A |
SEK50 ($7.4) |
Isconova carried out a fully subscribed rights issue of about $7.4M |
11/5/12 |
Isotechnika Pharma Inc. (Edmonton, Alberta) |
Private placement |
3.7U |
$0.151 |
Isotechnika completed the second tranche of its nonbrokered private placement, raising additional gross proceeds of $151,000 |
11/1/12 |
MEI Pharma Inc. (San Diego) |
Private placement |
N/A |
$27.5 |
MEI raised $27.5M through a private placement led by Vivo Ventures and New Leaf Venture Partners with participation from RA Capital Management and Three Arch Opportunity Fund |
11/6/12 |
NovaBay Pharmaceuticals Inc. (Emeryville, Calif.) |
Equity investment |
N/A |
$1.5 |
NovaBay received a $1.5M equity investment from Pioneer Pharma (Singapore) Pte. Ltd. |
11/6/12 |
Novelos Therapeutics Inc. (Madison, Wis.) |
Private placement |
2S and a W for 1S |
$2 |
Novelos placed the shares and warrant with a business unit of Renova Group |
11/6/12 |
Opexa Therapeutics Inc. (The Woodlands, Texas) |
Purchase agreement |
N/A |
(up to $16.5M) |
Opexa signed a purchase agreement for the sale, from time to time over a 30 month-period, of up to $1.5M of its common stock and for up to $15M of its common stock to Lincoln Park Capital Fund LLC |
11/7/12 |
Rexahn Pharmaceuticals Inc. (Rockville, Md.) |
Investment |
N/A |
$0.75 |
Rexahn received a $750,000 investment from Teva Pharmaceutical Industries Ltd. via purchase of Rexahn's common stock at a 120% premium over the previous closing price |
11/28/12 |
Spherix Inc. (Bethesda, Md.) |
Private placement |
0.484S and W for 0.484S |
$2.6 |
Closed agreements to sell $2.6 million of shares of its common stock together with warrants to purchase additional shares of its common stock |
11/13/12 |
Uluru Inc. (Addison, Texas) |
Investment |
5S |
$2 |
Uluru was to receive $2M in an equity investment from Melmed Holdings AG, selling 5M shares and warrants to purchase 3M shares, at 40 cents per share |
11/2/12 |
ValiRx plc (London) |
Private placement |
N/A |
£2.03 ($3.3) |
ValiRx raised $3.3M in the placement |
11/27/12 |
|
Notes: This chart does not include real estate or manufacturing plant financings, or debt deals done to replace existing debt. Loan money is included in the total only when it is drawn down, if disclosed. Currency conversions are based on exchange rates at the time of the deal. The date indicated refers to the BioWorld Today issue in which the news item can be found. N/A = Not applicable; ND = Not disclosed. | |||||